PE20060309A1 - (1r,2s,5s)-n-[(1s)-3-amino-1-(ciclobutilmetil)-2,3-dioxopropil]-3-[(2s)-2[[[(1,1-dimetiletil)amino]carbonil]amino]-3,3-dimetil-1-oxobutil]-6,6-dimetil-3-azabiciclo[3.1.o]hexan-2-carboxamida como inhibidor de la ns3/ns4a serina proteasa del virus de l - Google Patents

(1r,2s,5s)-n-[(1s)-3-amino-1-(ciclobutilmetil)-2,3-dioxopropil]-3-[(2s)-2[[[(1,1-dimetiletil)amino]carbonil]amino]-3,3-dimetil-1-oxobutil]-6,6-dimetil-3-azabiciclo[3.1.o]hexan-2-carboxamida como inhibidor de la ns3/ns4a serina proteasa del virus de l

Info

Publication number
PE20060309A1
PE20060309A1 PE2005000504A PE2005000504A PE20060309A1 PE 20060309 A1 PE20060309 A1 PE 20060309A1 PE 2005000504 A PE2005000504 A PE 2005000504A PE 2005000504 A PE2005000504 A PE 2005000504A PE 20060309 A1 PE20060309 A1 PE 20060309A1
Authority
PE
Peru
Prior art keywords
amino
dimethyl
hexan
cyclobutylmethyl
dimethylethyl
Prior art date
Application number
PE2005000504A
Other languages
English (en)
Inventor
F George Njoroge
Srikanth Venkatraman
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of PE20060309A1 publication Critical patent/PE20060309A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Abstract

SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE UN INHIBIDOR DE SERINA PROTEASA NS3/NS4A DEL VHC TAL COMO (1R,2S,5S)-N-[(1S)-3-AMINO-1-(CICLOBUTILMETIL)-2,3-DIOXOPROPIL]-3-[(2S)-2[[[(1,1-DIMETILETIL)AMINO]CARBONIL]AMINO]-3,3-DIMETIL-1-OXOBUTIL]-6,6-DIMETIL-3-AZABICICLO[3.1.O]HEXAN-2-CARBOXAMIDA, TAMBIEN PUEDE PRESENTARSE EN COMBINACION CON OTRO AGENTE ANTIVIRAL TAL COMO RIBAVIRINA, LEVOVIRINA, ENTRE OTROS, Y ADICIONALMENTE UN INTERFERON ALFA O PEGILADO, TAL COMO EL INTERFERON PEGILADO DE LA MARCA ITRON, PEGASYS, INFERGEN, ALFERON, ENTRE OTROS. ESTA COMPOSICION ES UTIL PARA EL TRATAMIENTO DE LA HEPATITIS C (VHC), HIV, SIDA Y ES ADECUADO PARA LA ADMINISTRACION ORAL, SUBCUTANEA, INTRAVENOSA O INTRATECAL
PE2005000504A 2004-05-06 2005-05-04 (1r,2s,5s)-n-[(1s)-3-amino-1-(ciclobutilmetil)-2,3-dioxopropil]-3-[(2s)-2[[[(1,1-dimetiletil)amino]carbonil]amino]-3,3-dimetil-1-oxobutil]-6,6-dimetil-3-azabiciclo[3.1.o]hexan-2-carboxamida como inhibidor de la ns3/ns4a serina proteasa del virus de l PE20060309A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US56872104P 2004-05-06 2004-05-06

Publications (1)

Publication Number Publication Date
PE20060309A1 true PE20060309A1 (es) 2006-04-13

Family

ID=34968691

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2005000504A PE20060309A1 (es) 2004-05-06 2005-05-04 (1r,2s,5s)-n-[(1s)-3-amino-1-(ciclobutilmetil)-2,3-dioxopropil]-3-[(2s)-2[[[(1,1-dimetiletil)amino]carbonil]amino]-3,3-dimetil-1-oxobutil]-6,6-dimetil-3-azabiciclo[3.1.o]hexan-2-carboxamida como inhibidor de la ns3/ns4a serina proteasa del virus de l

Country Status (5)

Country Link
US (1) US20050249702A1 (es)
AR (1) AR049635A1 (es)
PE (1) PE20060309A1 (es)
TW (1) TW200539889A (es)
WO (1) WO2005107745A1 (es)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU227742B1 (en) 1996-10-18 2012-02-28 Vertex Pharma Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease
SV2003000617A (es) 2000-08-31 2003-01-13 Lilly Co Eli Inhibidores de la proteasa peptidomimetica ref. x-14912m
AR045596A1 (es) 2003-09-05 2005-11-02 Vertex Pharma Inhibidores de proteasas de serina en particular proteasa ns3-ns4a del vhc
WO2006130686A2 (en) 2005-06-02 2006-12-07 Schering Corporation Hcv protease inhibitors in combination with food
BRPI0610737A2 (pt) 2005-06-02 2010-07-20 Schering Corp formulações farmacêuticas e métodos de tratamento usando as mesmas
US20110104109A1 (en) * 2005-07-13 2011-05-05 Frank Bennett Tetracyclic indole derivatives and their use for treating or preventing viral infections
EP2256113A1 (en) * 2005-08-02 2010-12-01 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases
AR055395A1 (es) 2005-08-26 2007-08-22 Vertex Pharma Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c
US7964624B1 (en) 2005-08-26 2011-06-21 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases
CA2629343A1 (en) 2005-11-11 2007-05-24 Vertex Pharmaceuticals, Inc. Hepatitis c virus variants
US7705138B2 (en) 2005-11-11 2010-04-27 Vertex Pharmaceuticals Incorporated Hepatitis C virus variants
AR056805A1 (es) * 2005-11-14 2007-10-24 Schering Corp Un proceso para oxidacion para la preparcion de n- (3- amino-1- ( ciclobutilmetil) -2,3- dioxopropil ) -3-(n-(( ter-butilamino) carbonil )-3- metil- l- valil) -6,6- dimetil-3- azabiciclo (3.1.0) hexano -2- carboxamida y compuestos ralacionados
US7816348B2 (en) 2006-02-03 2010-10-19 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
CA2643688A1 (en) 2006-02-27 2007-08-30 Vertex Pharmaceuticals Incorporated Co-crystals and pharmaceutical compositions comprising the same
CA2645684A1 (en) * 2006-03-06 2007-09-13 Abbott Laboratories Compositions and methods of use of ritonavir for treating hcv
EP1993994A2 (en) 2006-03-16 2008-11-26 Vertex Pharmceuticals Incorporated Deuterated hepatitis c protease inhibitors
RU2448976C2 (ru) * 2006-04-11 2012-04-27 Новартис Аг Ингибиторы hcv/вич и их применение
US20080045530A1 (en) * 2006-04-11 2008-02-21 Trixi Brandl Organic Compounds and Their Uses
CN101421292A (zh) * 2006-04-11 2009-04-29 诺瓦提斯公司 Hcv抑制剂
US20080193518A1 (en) * 2006-04-28 2008-08-14 Schering Corporation Process for the precipitation and isolation of 6,6-Dimethyl-3-Aza Bicyclo [3.1.0] Hexane-Amide compounds by controlled precipitation and pharmaceutical formulations containing same
US8420122B2 (en) * 2006-04-28 2013-04-16 Merck Sharp & Dohme Corp. Process for the precipitation and isolation of 6,6-dimethyl-3-aza-bicyclo [3.1.0] hexane-amide compounds by controlled precipitation and pharmaceutical formulations containing same
CN101506167A (zh) 2006-08-17 2009-08-12 贝林格尔.英格海姆国际有限公司 病毒聚合酶抑制剂
EP2121604A2 (en) * 2006-12-15 2009-11-25 Schering Corporation Bisulfite purification of an alpha-keto amide
US20100113821A1 (en) 2006-12-19 2010-05-06 Schering-Plough Corporation Preparation of 3-amino-3-(cyclobutylmethyl)-2-(hydroxy)-propionamide hydrochloride
CN101611000B (zh) * 2006-12-20 2013-08-21 默沙东公司 (1r,2s,5s)-n-[(1s)-3-氨基-1-(环丁基甲基)-2,3-二氧代丙基]-3-[(2s)-2-[[[(1,1-二甲基乙基)氨基]-羰基]氨基]-3,3-二甲基-1-氧代丁基]-6,6-二甲基-3-氮杂双环[3.1.0]己烷-2-碳酰胺的制备方法
AU2007339382B2 (en) 2006-12-22 2013-05-02 Merck Sharp & Dohme Llc 4,5-ring annulated indole derivatives for treating or preventing of HCV and related viral infections
JP5211068B2 (ja) * 2006-12-22 2013-06-12 メルク・シャープ・アンド・ドーム・コーポレーション Ｈｃｖおよび関連するウイルス疾患の治療または予防のための４，５−環インドール誘導体
JP5055377B2 (ja) 2006-12-22 2012-10-24 シェーリング コーポレイション ［５，６−環］環形成インドール誘導体およびその使用方法
WO2008074035A1 (en) 2006-12-27 2008-06-19 Abbott Laboratories Hcv protease inhibitors and uses thereof
GEP20125645B (en) 2007-02-27 2012-09-25 Vertex Pharma Co-crystals and pharmaceutical compositions comprising the same
MX2009009176A (es) 2007-02-27 2009-09-28 Vertex Pharma Inhibidores de serina-proteasas.
CA2693997C (en) 2007-08-03 2013-01-15 Pierre L. Beaulieu Viral polymerase inhibitors
WO2009032124A1 (en) * 2007-08-29 2009-03-12 Schering Corporation Substituted indole derivatives and methods of use thereof
US8143305B2 (en) * 2007-08-29 2012-03-27 Schering Corporation 2,3-substituted indole derivatives for treating viral infections
CN101842374A (zh) * 2007-08-29 2010-09-22 先灵公司 用于治疗病毒感染的2，3-取代的氮杂吲哚衍生物
JP5443360B2 (ja) 2007-08-30 2014-03-19 バーテックス ファーマシューティカルズ インコーポレイテッド 共結晶体およびそれを含む医薬組成物
AR068756A1 (es) 2007-10-10 2009-12-02 Novartis Ag Compuestos peptidicos, formulacion farmaceutica y sus usos como moduladores del virus de la hepatitis c
WO2009064848A1 (en) * 2007-11-16 2009-05-22 Schering Corporation 3-heterocyclic substituted indole derivatives and methods of use thereof
JP5416708B2 (ja) * 2007-11-16 2014-02-12 メルク・シャープ・アンド・ドーム・コーポレーション ３−アミノスルホニル置換インドール誘導体およびそれらの使用方法
CN101910130A (zh) * 2007-11-28 2010-12-08 先灵公司 制备用于形成6,6-二甲基-3-氮杂双环[3.1.0]己烷化合物的中间体的脱卤化氢方法
WO2009076747A1 (en) 2007-12-19 2009-06-25 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
CA2727620A1 (en) * 2008-06-13 2009-12-17 Schering Corporation Tricyclic indole derivatives and methods of use thereof
US8188137B2 (en) 2008-08-15 2012-05-29 Avila Therapeutics, Inc. HCV protease inhibitors and uses thereof
CA2734486A1 (en) 2008-08-20 2010-02-25 Southern Research Institute Substituted pyridine and pyrimidine derivatives and their use in treating viral infections
EP2326628A1 (en) 2008-08-20 2011-06-01 Schering Corporation Azo-substituted pyridine and pyrimidine derivatives and their use in treating viral infections
EP2326626B1 (en) 2008-08-20 2013-10-16 Merck Sharp & Dohme Corp. Ethenyl-substituted pyridine and pyrimidine derivatives and their use in treating viral infections
EP2331511A1 (en) 2008-08-20 2011-06-15 Schering Corporation Ethynyl-substituted pyridine and pyrimidine derivatives and their use in treating viral infections
RU2011127080A (ru) 2009-01-07 2013-02-20 Сайнексис, Инк. Производное циклоспорина для применения в лечении заражения вирусом гепатита с и вич
EP2416772A1 (en) * 2009-04-06 2012-02-15 PTC Therapeutics, Inc. Combinations of a hcv inhibitor such as bicyclic pyrrole derivatives and a therapeutic agent
US8512690B2 (en) * 2009-04-10 2013-08-20 Novartis Ag Derivatised proline containing peptide compounds as protease inhibitors
US20110182850A1 (en) * 2009-04-10 2011-07-28 Trixi Brandl Organic compounds and their uses
AU2010253791A1 (en) 2009-05-29 2011-11-24 Merck Sharp & Dohme Corp. Antiviral compounds composed of three linked Aryl moieties to treat diseases such as Hepatitis C
AU2010324871A1 (en) 2009-11-25 2012-06-14 Merck Sharp & Dohme Corp. Fused tricyclic compounds and derivatives thereof useful for the treatment of viral diseases
US20130156731A1 (en) 2009-12-22 2013-06-20 Kevin X. Chen Fused tricyclic compounds and methods of use thereof for the treatment of viral diseas
EP2536410B1 (en) 2010-02-18 2015-09-23 Merck Sharp & Dohme Corp. Substituted pyrimidine derivatives and their use in treating viral infections
SG183526A1 (en) 2010-03-09 2012-09-27 Merck Sharp & Dohme Fused tricyclic silyl compounds and methods of use thereof for the treatment of viral diseases
US20140377223A1 (en) 2010-07-26 2014-12-25 Joseph A. Kozlowski Substituted biphenylene compounds and methods of use thereof for the treatment of viral diseases
US9254292B2 (en) 2010-09-29 2016-02-09 Merck Sharp & Dohme Corp. Fused tetracycle derivatives and methods of use thereof for the treatment of viral diseases
EP2697242B1 (en) 2011-04-13 2018-10-03 Merck Sharp & Dohme Corp. 2'-azido substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
EA201391519A1 (ru) 2011-04-13 2014-03-31 Мерк Шарп И Доум Корп. 2'-замещенные нуклеозидные производные и способы их применения для лечения вирусных заболеваний
WO2013033901A1 (en) 2011-09-08 2013-03-14 Merck Sharp & Dohme Corp. Heterocyclic-substituted benzofuran derivatives and methods of use thereof for the treatment of viral diseases
WO2013033900A1 (en) 2011-09-08 2013-03-14 Merck Sharp & Dohme Corp. Tetracyclic heterocycle compounds and methods of use thereof for the treatment of viral diseases
WO2013033899A1 (en) 2011-09-08 2013-03-14 Merck Sharp & Dohme Corp. Substituted benzofuran compounds and methods of use thereof for the treatment of viral diseases
WO2013039876A1 (en) 2011-09-14 2013-03-21 Merck Sharp & Dohme Corp. Silyl-containing heterocyclic compounds and methods of use thereof for the treatment of viral diseases
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
TW201600087A (zh) 2011-10-21 2016-01-01 艾伯維有限公司 治療ｃ型肝炎病毒（ｈｃｖ）的方法
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
DK2583677T1 (da) 2011-10-21 2015-01-19 Abbvie Inc Fremgangsmåder til behandling af HCV omfattende mindst to direktevirkende antivirale midler, ribavirin, men ikke inteferon
ES2673870T3 (es) * 2012-05-07 2018-06-26 Bristol-Myers Squibb Holdings Ireland Formulación de dosificación oral sólida de [(1S)-1-{[(2S,4R)-4-(7-cloro-4-metoxiisoquinolin-1-iloxi)-2-({(1R,2S)-1-[(ciclopropilsulfonil) carbamoil]-2-etenilciclopropil} carbamoil) pirrolidin-1-il] carbonil}-2,2-dimetil-propil] carbamato de 1,1-dimetiletilo
WO2014083575A2 (en) 2012-11-29 2014-06-05 Mylan Laboratories Ltd Improved process for the preparation of boceprevir intermediate
WO2015004685A2 (en) 2013-07-12 2015-01-15 Mylan Laboratories Ltd An improved process for the purification of boceprevir
EP3063140A4 (en) 2013-10-30 2017-11-08 Merck Sharp & Dohme Corp. Pseudopolymorphs of an hcv ns5a inhibitor and uses thereof
JP7129703B2 (ja) 2016-04-28 2022-09-02 エモリー ユニバーシティー アルキン含有ヌクレオチド及びヌクレオシド治療組成物並びにそれらに関連した使用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL169273B1 (pl) * 1990-04-04 1996-06-28 Chiron Corp skierowanej przeciw wirusowi zapalenia watroby C PL
US7244721B2 (en) * 2000-07-21 2007-07-17 Schering Corporation Peptides as NS3-serine protease inhibitors of hepatitis C virus
KR100904788B1 (ko) * 2000-07-21 2009-06-25 쉐링 코포레이션 Ｃ형 간염 바이러스의 ｎｓ3-세린 프로테아제억제제로서의 신규한 펩티드
WO2004113295A1 (en) * 2003-06-17 2004-12-29 Schering Corporation Process and intermediates for the preparation of (1r,2s,5s)-6,6-dimethyl-3-azabicyclo[3,1,0]hexane-2-carboxylates or salts thereof
AR044694A1 (es) * 2003-06-17 2005-09-21 Schering Corp Proceso y compuestos intermedios para la preparacion de (1r, 2s,5s) - 3 azabiciclo [3,1,0] hexano-2- carboxamida, n- [3- amino-1- (ciclobutilmetil) - 2, 3 - dioxopropil] -3- [ (2s) - 2 - [[ [ 1,1- dimetiletil] amino] carbonilamino] -3,3-dimetil -1- oxobutil]-6,6 dimetilo

Also Published As

Publication number Publication date
AR049635A1 (es) 2006-08-23
US20050249702A1 (en) 2005-11-10
TW200539889A (en) 2005-12-16
WO2005107745A1 (en) 2005-11-17

Similar Documents

Publication Publication Date Title
PE20060309A1 (es) (1r,2s,5s)-n-[(1s)-3-amino-1-(ciclobutilmetil)-2,3-dioxopropil]-3-[(2s)-2[[[(1,1-dimetiletil)amino]carbonil]amino]-3,3-dimetil-1-oxobutil]-6,6-dimetil-3-azabiciclo[3.1.o]hexan-2-carboxamida como inhibidor de la ns3/ns4a serina proteasa del virus de l
JP2007522237A5 (es)
PE20080171A1 (es) Composicion farmaceutica que comprende la combinacion de al menos un inhibidor de la proteasa del virus de la hepatitis c y al menos un inhibidor de cyp3a4
HRP20110169T1 (hr) Upotreba [d-meala]3-[etval]4-ciklosporina za liječenje infekcija hepatitisom c
PL1658302T3 (pl) Analogi nukleozydów purynowych do leczenia chorób spowodowanych przez Flaviviridae obejmujących zapalenie wątroby typu C
EA201100506A1 (ru) Комбинация ингибитора протеазы ns3 hcv с интерфероном и рибавирином
PE20110212A1 (es) (1aR, 5S, 8S, 10R, 22aR)-5-TERT-BUTIL-N-{(1R, 2S)-1-{[(CICLOPROPILSULFONIL) AMINO] CARBONIL}-2-VINILCICLOPROPIL}-14-METOXI-3,6-DIOXO-1, 1a, 3, 4, 5, 6, 9, 10, 18, 19, 20, 21, 22, 22a-TETRADECAHIDRO-8H-7, 10-METANOCICLOPROPA[18, 19] [1, 10, 3, 6] DIOXADIAZACICLONONADECINO[11, 12-b] QUINOXALIN-8-CARBOXAMIDA COMO INHIBIDOR DE LA PROTEASA HCV NS3
PE20071230A1 (es) Combinaciones y metodos de inhibidores del vhc
HK1068538A1 (en) Antiviral compounds
ATE471144T1 (de) Intranasale verabreichung von schnell wirkendem insulin
WO2006130627A3 (en) Methods for treating hepatitis c
JP2010528013A5 (es)
RU2012136824A (ru) Способы лечения вирусной инфекции гепатита с
PE20091164A1 (es) Inhibidores macrociclicos de la ns3 serina proteasa del virus de la hepatitis c
EA200501699A1 (ru) Стабилизированные жидкие композиции интерферона, не содержащие человеческий сывороточный альбумин
RU2010153688A (ru) Режим дозирования телапревира
Gane et al. Safety and efficacy of short-duration treatment with GS-9857 combined with sofosbuvir/GS-5816 in treatment-naïve and DAA-experienced genotype 1 patients with and without cirrhosis
WO2008073864A8 (en) Novel combinations
RS105104A (en) Treatment of hepatitis c in asian population with subcutaneous interferonbeta
UA95299C2 (ru) Профилактический или терапевтический агент против вирусного заболевания, вызванного вирусом гепатита с
EA200501569A1 (ru) Лечение или профилактика респираторных вирусных инфекций с использованием пептидов альфа-тимозина
AR036698A1 (es) Metodo para el tratamiento de la infeccion por virus de hepatitis c en pacientes sin respuesta a tratamiento
WO2004096197A8 (en) 5-aza-7-deazapurine nucleosides for treating flaviviridae
MXPA05007901A (es) Terapia de combinacion para hcv.
Ikramaliyevich et al. VIROCIDAL ACTIVITY OF EGYPTIAN SCORPION VENOMS AGAINST HEPATITIS C VIRUS

Legal Events

Date Code Title Description
FD Application declared void or lapsed